We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

How The FDA Can Compel Post-Marketing Studies

Law360 (April 29, 2011, 5:21 PM EDT) -- The U.S. Food and Drug Administration announced in the Federal Register on April 1 the availability of a draft guidance for industry titled “Post-Marketing Studies and Clinical Trials — Implementation of...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.